Desitin

🚨 Desitin (Johnson & Johnson) Boycott Reasons and Overview

Desitin is a registered brand operating under the American multinational pharmaceutical, medical technology, and healthcare conglomerate Johnson & Johnson (J&J). The inclusion of Desitin on boycott lists is directly tied to J&J's direct operational, military-medical, and institutional ties with israel:

• Six israeli Subsidiaries & Military Bio-Defense: J&J operates six registered subsidiaries in israel, including Omrix Biopharmaceuticals, which manufactures specialized biosurgical and medical-countermeasure technologies integrated with israeli military healthcare infrastructure.
• israel Innovation Authority (IIA) Collaboration & Multi-Billion Tech Injections: J&J co-manages the FutuRx biotech incubator in partnership with the israeli government and recently acquired israeli medical tech firm V-Wave for $1.7 billion in 2024, injecting substantial direct capital into israel's economy.
• Unit 8200 Cybersecurity & Surveillance Integration: Independent digital audits confirm J&J's enterprise dependency on israeli military intelligence (Unit 8200)-linked vendors, including CyberArk, SentinelOne, and biometric intelligence providers.
• Institutional Ownership Tied to Weapons Manufacturing: J&J's principal shareholders are BlackRock (8.80%) and Vanguard (7.09%), both documented in UN Human Rights Council reports as key financiers of arms manufacturers supplying the israeli military.
• Ethical Double Standards: While curtailing new business in Russia citing corporate ethics, J&J made direct multi-million-dollar corporate donations to israeli institutions following October 2023 while maintaining full commercial operations amidst catastrophic healthcare collapse in Gaza.

Revenues generated from Desitin flow directly into Johnson & Johnson's consolidated corporate accounts. For complete medical and defense audit records, visit the 👉 Johnson & Johnson Boycott Dossier.